The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
 
Julie Gralow
Consulting or Advisory Role - Genentech; Novartis
Research Funding - Amgen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
William E. Barlow
No Relationships to Disclose
 
Alexander H. G. Paterson
Stock and Other Ownership Interests - Pfizer; Roche
Honoraria - Novartis
Consulting or Advisory Role - Amgen; Roche
Research Funding - Amgen (Inst)
Expert Testimony - Teva
Travel, Accommodations, Expenses - Novartis
 
Danika Lew
No Relationships to Disclose
 
Alison Stopeck
Honoraria - Amgen; GlaxoSmithKline
Consulting or Advisory Role - Amgen; Bayer; Clovis Oncology; Genentech; Pfizer
Speakers' Bureau - Genomic Health
Research Funding - Amgen (Inst); Bayer (Inst); Novartis (Inst); Peregrine Pharmaceuticals (Inst); Puma Biotechnology (Inst)
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - 3rd UK Breast Cancer Meeting, Londong; Lilly
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.; Title: Circulating tumor cell capturing techniques and devices. Original application no. 61/593,092.; Title: Diagnosis and treatment of breast cancer. Original application no. 61/079,642; Revised application no. 61/224,310.
 
Dawn L. Hershman
No Relationships to Disclose
 
Mark Schubert
Consulting or Advisory Role - Amgen
 
Mark J. Clemons
No Relationships to Disclose
 
Catherine H. Van Poznak
Research Funding - Amgen (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Elizabeth Claire Dees
Consulting or Advisory Role - Amgen (I); Novartis (I)
Research Funding - Agensys; Bayer; Genentech/Roche; Lilly/ImClone; Millennium; Novartis; Pfizer
 
James N. Ingle
No Relationships to Disclose
 
Carla Isadora Falkson
No Relationships to Disclose
 
Anthony D. Elias
Consulting or Advisory Role - Genentech
Research Funding - Astellas Pharma (Inst); Genentech (Inst); Medivation (Inst)
 
Michael J. Messino
No Relationships to Disclose
 
Jeffrey H. Margolis
No Relationships to Disclose
 
Shaker R. Dakhil
No Relationships to Disclose
 
Helen K. Chew
No Relationships to Disclose
 
Robert B. Livingston
No Relationships to Disclose
 
Gabriel N. Hortobagyi
Consulting or Advisory Role - Amgen; Antigen Express; Galena Biopharma; Genentech; Novartis; Peregrine Pharmaceuticals; Pfizer
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Novartis